Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

XBI Guru Trades in

Q1 2016

XBI Guru Trades in Q1 2016

First Eagle Investment 18,150 sh (New)
» More
Q2 2016

XBI Guru Trades in Q2 2016

Steven Cohen 191,000 sh (New)
First Eagle Investment 18,150 sh (unchged)
» More
Q3 2016

XBI Guru Trades in Q3 2016

Louis Moore Bacon 100,000 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen 152,500 sh (-20.16%)
» More

Ratios

vs
industry
vs
history
P/B 4.65
XBI's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 4.65 )
Ranked among companies with meaningful P/B only.
XBI' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.69
Current: 4.65
0
5.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.48
XBI's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.48 )
Ranked among companies with meaningful Dividend Yield only.
XBI' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.52
Current: 0.48
0
0.52
Yield on cost (5-Year) 0.48
XBI's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.48 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XBI' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.52
Current: 0.48
0
0.52

More Statistics

Short Percentage of Float0.00%
52-Week Range $45.73 - 71.54
Shares Outstanding (Mil)49,500,000.00
» More Articles for XBI

Headlines

Articles On GuruFocus.com
2017 GuruFocus Conference Early Bird Registration Will End on December 15 Dec 06 2016 
Agilent Technologies Raises Dividend 15% Dec 06 2016 
Rising Rates Meet Nesting Urges Dec 06 2016 
Can Zest Fresh Revolutionize an Industry? Dec 06 2016 
Microsoft’s Downside Dec 06 2016 
24 Questions With Value Investor Jacob Taylor of the UC Davis Graduate School of Management Dec 06 2016 
Barnes & Noble Education Reports Sales Slump Dec 06 2016 
Nihon Kagaku Sangyo Looks Undervalued Dec 06 2016 
Why Palo Alto Networks Is the Best Cybersecurity Play Dec 06 2016 
AbbVie, Johns Hopkins Unite for Cancer Research Dec 06 2016 

More From Other Websites
Biotech & Pharma ETFs to Suffer in 2017 Too? Dec 08 2016
3 Reasons To Shrug Off Trump's Rhetoric On Drug Prices Dec 08 2016
Why Biotech is Getting Killed…And Why It WIll Bounce Back Dec 08 2016
Bad Day for Biotechs Means It's Time to Buy Dec 07 2016
Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers Dec 07 2016
Dow Scores Another Record for Third Consecutive Day; S&P 500 Also Hits New High Dec 07 2016
Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally Dec 07 2016
President-elect Trump’s promise to bring down drug prices sends biotech and pharma ETFs slumping Dec 07 2016
Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower Dec 07 2016
Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares Dec 07 2016
This indicator says the stock market’s celebration has gone too far Dec 07 2016
Biotech ETFs: So Much For The Trump Bounce Dec 07 2016
Bernie Sanders' 'Trump Proposal' To Lower Drug Prices Blocked By Senate Republicans Dec 07 2016
Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall Dec 07 2016
Trump: I'm Going To Bring Down Drug Prices Dec 07 2016
President-elect Trump's biotech comments sharply lower biotech ETFs Dec 07 2016
Billionaire Rob Citrone’s Monster Q3 Buys: Kellogg, Macy’s, Activision-Blizzard, More Dec 04 2016
Gundlach warns Trump trade is ‘losing steam’ and stocks have peaked Dec 02 2016
Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK